Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (247,558)	$ (147,946)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24,918	15,345
Amortization and impairment of internal-use software	3,214	1,741
Stock-based compensation expense	93,768	37,473
Change in fair value of warrant liabilities	0	(32,989)
Impairment of long-lived assets	10,126	0
Other	(1)	77
Changes in operating assets and liabilities:
Accounts receivable (includes related party amounts of $(3,636) and $(105), respectively)	(23,428)	(21,078)
Inventories	(1,172)	(10,605)
Deferred cost of revenue	(6,636)	(10,630)
Prepaid expenses and other current assets	3,772	(7,697)
Operating lease right-of-use assets	5,570	5,265
Other assets	(711)	(604)
Accounts payable (includes related party amounts of $(12,567) and $(4,422), respectively)	(23,305)	(804)
Accrued and other current liabilities (includes related party amounts of $4,090 and $5,416, respectively)	4,265	9,878
Deferred revenue (includes related party amounts of $13,762 and $(3,969), respectively)	45,996	40,223
Operating lease liabilities	(6,708)	(5,655)
Other liabilities	(2,539)	(3,617)
Net cash used in operating activities	(120,429)	(131,623)
Cash flows from investing activities:
Purchases of property and equipment	(2,854)	(2,420)
Purchases of intangible assets	0	(5,500)
Capitalized internal-use software costs	(5,163)	(2,855)
Cash paid for acquisitions, net of cash acquired	0	(94,165)
Net cash used in investing activities	(8,017)	(104,940)
Cash flows from financing activities:
Proceeds from exercise of stock options	3,933	11,476
Proceeds from issuance of common stock under employee stock purchase plan	3,238	0
Payments of deferred offering costs	0	(30,642)
Proceeds from issuance of common stock upon merger	0	309,720
Proceeds from PIPE (related party amounts of zero and $25,000, respectively)	0	250,000
Proceeds from exercise of merger warrants	0	44
Payment for warrant redemptions	0	(116)
Net cash provided by financing activities	7,171	540,482
Effect of exchange rates on cash	694	(4)
Net increase (decrease) in cash and restricted cash	(120,581)	303,915
Cash and restricted cash—beginning of period	561,755	290,862
Cash and restricted cash—end of period	441,174	594,777
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment during the period included in accounts payable and accrued expenses	472	859
Stock-based compensation capitalized for internal-use software costs	2,239	745
Reclassification of deferred offering costs	0	3,971
Assumption of merger warrants liability	0	75,415
Conversion of redeemable convertible preferred stock to common stock	0	837,351
Redemption/Exercise of Class A Common Stock Warrants	0	42,354
Stock consideration in acquisition of businesses, including fair value of common stock issued and fair value of stock-based awards that were vested	0	322,842
Cash and cash equivalents	432,801	586,204
Restricted cash, current	1,399	1,599
Restricted cash, non-current	6,974	6,974
Cash and cash equivalents	432,801
Total cash, cash equivalents and restricted cash	$ 441,174	$ 594,777